Cannliv Announces Cannabinoid Research Alliance
DENVER, May 2, 2018 (Newswire.com) - Cannliv today announced a Strategic Alliance with The University of Texas MD Anderson Cancer Center for pre-clinical research of the effects of Cannabinoids on cancer cells and developing therapies for treating cancers based on this research. Under the direction of Richard Ford, MD, Ph.D. and Lan Pham, Ph.D., Department of Hematopathology, Division of Pathology and Laboratory Medicine at MD Anderson, this 5-year agreement will explore the potential for cancer treatments using naturally occurring Cannabinoids that contain no tetrahydrocannabinol (THC). As part of the alliance, Cannliv, a Denver-based Hemp Product Research and Development Company specializing in emerging U.S. and International Markets, will provide proprietary Cannabinoid products, immutable ledger integrated Enterprise Resource Planning (ERP) solutions, and full access to its vast network of Cannabinoid knowledge.
“We could not be more pleased and humbled by the possibilities of this relationship,” stated John David Carrasco, Cannliv President and CEO. “This collaboration with MD Anderson allows us to investigate the effects of Cannabinoids on cancer cells in ways never thought possible.” He went on to say that “by implementing the latest in technology, we will create a truly transparent Chain of Custody to ensure patients and consumers know exactly how products are developed, the results and data from the research, and what they are putting in their bodies. Most importantly this allows us to seamlessly integrate patient data with treatment protocols in order to ensure best possible outcomes.”
Cannliv Colorado LLC is a privately-owned company based in Denver Colorado. Cannliv has developed products with Cannabinoids since October 2015 along with their solution to assist companies to achieve an immutable compliance level within the medical cannabis space using Ledger technology. Cannliv also has divisions in South America since August 2016. For additional information or collaboration inquiries, contact Wade Leach, Investor and Relations Consultant for Cannliv.